

Nexien BioPharma, Inc (OTC: NXEN) CEO Interview with Alex Wasyl discussing the company’s cannabinoid-based drug development pipeline. Drug development targets include, epliepsy, myotonia and other markets.


Nexien BioPharma, Inc (OTC: NXEN) CEO Interview with Alex Wasyl discussing the company’s cannabinoid-based drug development pipeline. Drug development targets include, epliepsy, myotonia and other markets.
Trulieve Cannabis (OTC: TCNNF) Largest Medical Cannabis Co. In Florida with 80,000 patients. CEO Interview with Kim Rivers Get our FREE Newsletter! Discover Stocks with +1,000% Upside Potential! Thank you for subscribing. Something went wrong. […]
VANCOUVER, Washington, Sept. 09, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that […]
The event further establishes LALPINA CBD’s connection to professional athletes as the Company looks to penetrate the $30 billion US fitness market PLAYA VISTA, Apr 25, 2019 – American Premium Water Corporation(OTC: HIPH) announces that […]
Copyright 1997-2019 Wall Street Reporter / Octagon Media Corp.
